Trial was conducted on participants 6 years and older.
Now approved for 2 years and up . Greater than 10 %
chance of adverse reactions.
Median age circa 44
While severe (grade III-IV) aGVHD-free-survival assessed at Day 180 after transplantation was not significantly improved in patients who received Orencia compared to patients who received a placebo (HR 0.55; 95% CI 0.26, 1.18), the OS rate at Day 180 after HSCT was 97% (95% CI: 89%, 99%) for patients who received abatacept compared to 84% (95% CI: 73%, 91%) for patients who received a placebo (HR 0.33; 95% CI: 0.12, 0.93). The moderate-severe (grade II-IV) aGVHD-free survival rate at Day 180 after HSCT was 50% (95% CI: 38%, 61%) for patients who received abatacept compared to 32% (95% CI: 21%, 43%) for patients who received a placebo (HR 0.54; 95% CI: 0.35, 0.83).
Ann: Biotech Showcase 2023 Presentation in San Francisco, page-158
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |